This single-center study utilizes real-world data (2012-2024) from 4700 renal cell carcinoma (RCC) patients at Peking University Third Hospital to: (1) Develop and validate a prognostic prediction model specifically for RCC patients, including those with venous tumor thrombus (VTT); (2) Compare the performance of this new model against existing RCC prediction models in both the overall RCC cohort and the VTT subgroup; (3) Employ an emulated target trial (ETT) methodology to evaluate whether risk-stratified treatment based on the prediction model (grouping patients as high/medium/low risk) improves survival outcomes .
Adults ≥18 years of age;
Diagnosis of primary renal cell carcinoma before and during the surgery;
Received radical nephrectomy/nephron-sparing surgery.
Subjects with severely missing clinical information;
History of other malignant tumors.
Recurrence observed before first postoperative follow-up.
Discontinue the adjuvant treatment within in the first two course because of severe adverse react.